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Bisphenol A (BPA) is one of the highest vol-
ume chemicals produced worldwide, with 
> 8 billion pounds produced each year and 
> 100 tons released into the atmosphere by 
yearly production. Data from multiple sources 
indicate that the amount of BPA to which 
humans are exposed may cause adverse health 
effects; this has raised concerns among regula-
tory agencies all over the world.
As an essential component of poly-
carbonate plastic, BPA is found in numerous 
consumer products, including baby bottles, 
reusable water bottles, reusable food contain-
ers, polyvinyl chloride stretch films, papers, 
and cardboards (reviewed by Vandenberg 
et al. 2007). Metallic food and beverage cans 
are protected from rusting and corrosion 
by the application of epoxy resins as inner 
coatings. The synthesis of many of these   
resins requires the condensation of BPA with 
epichlorohydrin to create BPA diglycidyl ether. 
When incomplete polymerization occurs, 
residual BPA leaches from the epoxy resin. 
High temperatures and exposure to acidic or 
basic solutions can also increase leaching of 
BPA from coatings and plastics, even when 
complete polymerization has occurred. More 
than 10 studies have detected BPA leach-
ing from the linings of metal cans into foods 
(Vandenberg et al. 2007). BPA has also been 
detected in a variety of environmental samples, 
including water, sewage leachates, indoor and 
outdoor air samples, and dust (Vandenberg 
et al. 2007). It is also found in papers and in 
implanted medical devices and other medical 
equipment (Welshons et al. 2006).
BPA attracted the attention of regulatory 
agencies and scientists in dozens of countries 
because of its estrogenic properties in vitro and 
in vivo and the conserved role that estrogen 
plays in regulating human and animal physiol-
ogy and pathophysiology (Dodds and Lawson 
1936; Markey et al. 2001; Wetherill et al. 
2007). Biochemical assays have examined the 
kinetics of BPA binding to the estrogen recep-
tors (ERs) and have determined that BPA 
binds both ERα and ERβ, with approximately 
10 times higher affinity for ERβ (Gould et al. 
1998; Kuiper et al. 1998). Until recently, BPA 
was considered a weak environmental estrogen 
because of its relatively low affinity for the 
nuclear ERs compared with estradiol in some 
assays (Andersen et al. 1999; Fang et al. 2000). 
However, results from several studies have 
revealed that BPA can stimulate rapid cellu  lar 
responses at very low concentrations, below 
the levels where BPA is expected to bind to 
the classical nuclear ERs (Welshons et al. 
2006). BPA has also been shown to bind to 
a membrane-associated ER and produce non-
genomic steroid actions (Wetherill et al. 2007) 
with the same efficacy and potency as estradiol 
(Alonso-Magdalena et al. 2005; Hugo et al. 
2008). Whatever the mechanism, BPA can 
cause effects in animal models at doses in the 
range of human exposures, indicating that it 
can act at lower doses than predicted from 
some in vitro and in vivo assays (Richter et al. 
2007; Vandenberg et al. 2007; vom Saal et al. 
2007; Wetherill et al. 2007).
For risk assessment, a reference dose 
(RfD) is calculated as an acceptable daily 
human intake, typically 100-fold less than the 
no observed adverse effect level (NOAEL). 
However, the RfD for BPA (50 µg/kg/day) 
was calculated using the lowest observable 
adverse effect level (LOAEL) and 1,000-fold 
safety factors because a NOAEL had not been 
determined (Welshons et al. 2003). More than 
150 published studies describe BPA effects in 
animals exposed to < 50 mg/kg/day, including 
altered develop  ment of the male and female 
reproductive tracts, organization of sexu-
ally dimorphic circuits in the hypothalamus, 
onset of estrus cyclicity and earlier puberty, 
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Ba c k g r o u n d: Bisphenol A (BPA) is one of the highest-volume chemicals produced worldwide, 
and human exposure to BPA is thought to be ubiquitous. Thus, there are concerns that the amount 
of BPA to which humans are exposed may cause adverse health effects. Importantly, results from a 
large number of biomonitoring studies are at odds with the results from two toxico  kinetic studies. 
oB j e c t i v e: We examined several possibilities for why biomonitoring and toxico  kinetic studies 
could come to seemingly conflicting conclusions.
da t a s o u r c e s: We examined > 80 published human biomonitoring studies that measured BPA 
concentrations in human tissues, urine, blood, and other fluids, along with two toxico  kinetic studies 
of human BPA metabolism. 
da t a e x t r a c t i o n a n d synthesis: The > 80 biomonitoring studies examined included measure-
ments in thousands of individuals from several different countries, and these studies overwhelmingly 
detected BPA in individual adults, adolescents, and children. Unconjugated BPA was routinely 
detected in blood (in the nanograms per milliliter range), and conjugated BPA was routinely detected 
in the vast majority of urine samples (also in the nanograms per milliliter range). In stark contrast, 
toxico  kinetic studies proposed that humans are not internally exposed to BPA. Some regulatory 
agencies have relied solely on these toxicokinetic models in their risk assessments.
co n c l u s i o n s: Available data from biomonitoring studies clearly indicate that the general population 
is exposed to BPA and is at risk from internal exposure to unconjugated BPA. The two toxico  kinetic 
studies that suggested human BPA exposure is negligible have significant deficiencies, are directly 
contradicted by hypothesis-driven studies, and are therefore not reliable for risk assessment purposes.
key w o r d s : endocrine disruptor, human exposure, PBPK/PBTK model, pregnancy, risk assess-
ment, toxicokinetics. Environ Health Perspect 118:1055–1070 (2010).  doi:10.1289/ehp.0901716 
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altered body weight, altered organization of 
the mammary gland, and cancers of the mam-
mary gland and prostate; > 40 of these studies 
examined doses less than the RfD (Richter 
et al. 2007). Many of these end points are in 
areas of current concern for human epidemio-
logical trends (Soto et al. 2008; Vandenberg 
et al. 2009). Indeed, it has been suggested that 
exposure to xeno  estrogens such as BPA dur-
ing early development may be a major con-
tributing factor to the increased incidence of 
infertility, genital tract abnormalities, obesity, 
attention deficit hyperactivity disorder, infer-
tility, and prostate and breast cancer observed 
in European and U.S. human populations 
over the last 50 years (Sharpe and Skakkebaek 
1993; Soto et al. 2008).
There is great concern about exposure of 
human fetuses, infants, and neonates to BPA 
because of the sensitivity of the developing 
organs and brain to exogenous hormones 
(Vandenberg et al. 2009). However, for 
translating the findings from animal studies   
to health risks of environmental exposures 
to humans, exposure assessment from bio-
monitoring of BPA in different populations 
is essential.
In this review, we examined > 80 biomon-
itoring studies that measured BPA concentra-
tions in human tissues and fluids, specifically 
focusing on individuals that were exposed 
to BPA via their environment (i.e., non-
occupational exposures). These studies, exam-
ining thousands of individuals from several 
different countries, overwhelmingly detected 
BPA in individual adults, adolescents, and 
children. Interestingly, results from the large 
body of research encompassing biomonitoring 
studies are at odds with the results from two 
toxico  kinetic studies that determined the dis-
position of BPA in humans after oral adminis-
tration of BPA (Volkel et al. 2002, 2005). 
Volkel et al. (2002) reported that after oral 
absorption, BPA was promptly metabolized 
in the liver and intestines. However, find-
ings from the > 80 biomonitoring studies we 
reviewed support the hypothe  sis that hepatic 
metabolism of BPA or its pre  systemic clear-
ance is not 100% efficient, because unconju-
gated BPA has been regularly detected in urine 
and blood samples. Theoretically, the pres-
ence of unconjugated BPA in blood and/or   
urine samples could also be explained by 
exposure via non-oral routes that circum-
vent liver and intestinal first-pass metabolism 
(Stahlhut et al. 2009). All sources for oral 
and non-oral exposures have not been defini-
tively identified, thus increasing the value of 
biomonitoring studies, which do not take into 
account exposure sources. Throughout this 
review, when we discuss conjugated BPA it is 
specifically identified; otherwise, “BPA” refers 
to the unconjugated mole  cule. Note also that 
when we identify significant differences, we 
are referring to statistically significant differ-
ences identified by the original study authors, 
each of whom established a relevant α-value 
for their study populations. 
In this review, we propose several hypothe-
ses to explain why biomonitoring and toxico-
kinetic studies could come to seemingly 
conflicting conclusions. Additionally, the reli-
ance of regulatory agencies on the two studies 
that predict no human exposure, in contrast to 
the > 80 studies that measure actual internal 
exposures, is contrary to scientific principles. 
Biomonitoring Studies: 
General Overview
Biomonitoring studies allow the determina-
tion of internal circulating levels and excreted 
concentrations of a chemical of interest, 
which account for exposures from all possi-
ble sources, rather than suspected exposures 
from specific sources. In the United States, the 
Centers for Disease Control and Prevention 
(CDC) is the major source for information on 
human exposures to a multi  tude of environ-
mental contaminants and has developed sen-
sitive assays to reliably measure them (CDC 
2008; Kuklenyik et al. 2009). In Europe, the 
German Environmental Survey is a repre-
sentative population study to determine the 
exposure of Germany’s general population to 
environmental contaminants (Umwelt Bundes 
Amt 2009). Its main objective is to gener-
ate, update, and evaluate representative data 
in order to facilitate environmental health–
related observations and reporting of informa-
tion at the national level.
Proper biomonitoring studies take into 
account the kinetics, bioaccumulative proper-
ties, and metabolism of the target chemical 
to determine which tissue (biological matrix) 
should be examined. The chemical properties 
of the substance being examined also have an 
impact on the matrices that can be examined 
reliably, because some substances are altered 
by enzymes in blood and other substances can 
break down in urine (Calafat and Needham 
2008). Furthermore, the toxico  kinetics of the 
substance being investigated is likely to be 
influenced by the physiological status of the 
individual. Finally, the sensitivity and reli-
ability of the methods used for analysis, the 
collection methods and materials, and the 
contamination of laboratory chemicals and 
equipment with the substance of interest 
are all important factors to be considered in 
biomonitoring studies. We discuss these issues 
in greater detail below.
Analytical Methods Used in 
Biomonitoring Studies
Multiple techniques have been used to meas-
ure total, unconjugated, and conjugated BPA 
in human blood, urine, and tissue samples. 
Gas chromatography (GC) and liquid 
chromatography (LC) are typically used with 
various detection methods, including mass 
spectrometry (MS), tandem MS (MS/MS), 
and electro  chemical or fluorescence deriva-
tization. The CDC has measured BPA using 
solid-phase extraction coupled with isotope 
dilution–HPLC (high-performance liquid 
chromatography)–MS/MS, which is con-
sidered the “gold standard” for urine bio-
monitoring studies because of its high level of 
accuracy, negligible interference, and ability 
to identify chemical structures (Calafat et al. 
2008). However, this method is limited by its 
high cost per sample, making it impractical 
for many studies.
The methods used in biomonitoring stud-
ies are crucial for the acceptance of the results 
(Dekant and Volkel 2008; Vandenberg et al. 
2007). The ELISA (enzyme-linked immuno-
sorbent assay) has also been used in several 
studies of human fluids and tissues because 
it is convenient, inexpensive, and useful for 
the screening of a large number of samples. 
However, the use of ELISA to meas  ure BPA 
concentrations in human samples has been 
specifically challenged because this method is 
considered less specific than methods employ-
ing analytical chemis  try (Dekant and Volkel 
2008; Fukata et al. 2006); that is, there is 
concern that ELISA assays detect substances 
other than BPA and its conjugates, includ-
ing other bisphenols (Ohkuma et al. 2002). 
Studies rarely report the controls that are 
necessary to determine whether or not cross-
reactivity has occurred; however, if infor-
mation about cross-reactivity and standard 
validations are included, these data should 
be considered valid, as they are for the many 
other compounds that are measured with this 
method. In general, ELISA has fallen out of 
favor for the quantification of BPA in human 
biomonitoring studies, particularly because 
more sensitive, accurate, and precise methods 
employing analytical chemistry are now avail-
able for high-throughput screens (Kuklenyik 
et al. 2009). Nonetheless, it should be recog-
nized that this method is much more afford-
able than analytical chemistry methods and, 
most important, it has successfully been used 
to measure BPA in samples in a comparable 
dose range and in a similar percentage of sam-
ples as the methods that are considered more 
accurate (Vandenberg et al. 2007).
In addition to the methods used to meas-
ure BPA in human tissues and fluids, the 
equipment and containers used to collect 
and store samples are critical for the accu-
rate assessment of BPA concentrations. It has 
been suggested that the low levels of uncon-
jugated BPA detected in bodily tissues and 
fluids were due to contamination from col-
lection materials or non  enzymatic deconjuga-
tion of BPA during storage (Atkinson et al. 
2002; Dekant and Volkel 2008; Willhite Biomonitoring suggests widespread BPA exposure
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et al. 2008). Organic solvents used in the 
labora  tory may release BPA from plastic lab-
ware, leading to contamination; water has 
also been found to contain detectable levels 
of BPA (Vandenberg et al. 2007), and the 
columns used for HPLC may contain and/or   
trap BPA (Volkel et al. 2005). For these rea-
sons, the use of adequate blanks is essential 
for every step of the biomonitoring process, 
including sample collection and every point 
in the chemical analysis. These blanks should 
be subjected to the same extraction/injection 
protocols as the actual samples. Most of the 
biomonitoring studies we reviewed included 
data from blanks to indicate that, contrary to 
the claims made by some scientists (Dekant 
and Volkel 2008), contamination from equip-
ment cannot explain the concentrations of 
BPA reported.
In terms of sample collection, stud-
ies should control for contamination from 
syringes used to draw samples, pipettes used 
to transfer plasma/serum to storage tubes, and 
the nature of sample storage tubes. If samples 
are obtained in hospital settings where the 
patient has an intravenous tube, it is essen-
tial to account for BPA leaching from these 
tubes during saline infusion. Studies need to 
be performed using appropriate matrix (blood 
or urine) spiked with known amounts of BPA 
and subjected to collection procedures similar 
to that of actual sampling to rule out BPA 
contribution from these various sources. One 
study used sheep blood to perform such vali-
dations and found very little BPA contamina-
tion from these sources (Padmanabhan et al. 
2008). However, for translation to humans, 
similar studies using human blood and/or 
urine need to be undertaken.
Ye et al. (2007) addressed the issue of   
sample storage by comparing the stability of 
BPA conjugates for urine stored for up to 
6 months at three temperatures: room tem-
perature, 4°C, or –70°C. Storage at –70°C 
kept conjugated BPA stable for at least 180 
days, whereas storage at room temperature 
led to degradation of BPA conjugates within 
24 hr. The effects of storage temperature on 
the detection of BPA and BPA conjugates 
in saliva samples have also been investi-
gated. Atkinson et al. (2002) spiked saliva 
samples with BPA, BPA dimethylacrylate 
(Bis-DMA), or tri  ethylene glycol dimethacry-
late (TEGDMA), stored at –20°C or –70°C, 
and then tested the samples by HPLC and 
GC-MS. In contrast to samples stored at 
–20°C, concentrations of BPA, Bis-DMA, 
and TEGDMA were unchanged in salivary 
samples stored at –70°C, suggesting that this 
condition was appropriate for biological sam-
ple storage. Finally, in a recent study Ye et al. 
(2009b) examined the stability of phenols 
in 16 commercially available serum samples 
stored under worst-case–scenario conditions 
(4°C, 25°C, or 37°C). Concentrations of 
BPA metabolites and other phenols did not 
vary significantly, even when samples were 
stored at 37°C for at least 30 days. This find-
ing suggests that phenolic compounds, likely 
including BPA, are more stable in serum 
than in urine, and it gives greater credence to 
those studies that measured BPA in human 
serum samples. 
Exposure Assessment from 
Urinary Measures of BPA
In 2001, the CDC conducted the first 
biomonitoring study of BPA (unconjugated 
and conjugated) in pooled urine samples 
(Brock et al. 2001). The authors developed 
a method that was fairly sensitive [limit of 
detection (LOD) = 0.12 ng/mL]; concentra-
tions of unconjugated BPA were < LOD, and 
concentrations of BPA glucuronide ranged 
from 0.11 to 0.51 ng/mL. After this initial 
examination in pooled urine, more than a 
dozen additional small studies examined uri-
nary BPA concentrations and/or its metabo-
lites in < 100 adults each (Arakawa et al. 2004; 
Carwile et al. 2009; García-Prieto et al. 2008; 
Joskow et al. 2006; Kawaguichi et al. 2005; 
Kim et al. 2003; Liu et al. 2005; Mao et al. 
2004; Matsumoto et al. 2003; Moors et al. 
2007; Nepomnaschy et al. 2009; Ouichi and 
Watanabe 2002; Schöringhumer and Cichna-
Markl 2007; Tsukioka et al. 2003; Volkel 
et al. 2005; Yang et al. 2003; Ye et al. 2005a, 
2005b) (Table 1). Although these studies used 
slightly different methods and different popu-
lation samples, they overwhelmingly detected 
BPA or its conjugates in urine. Collectively, 
these studies examined spot urine samples col-
lected from 604 adults, and BPA and/or its 
conjugates were detected in 518 (85.8%).
Because most studies of urine used enzy-
matic treatment with either glucuronidase or 
sulfatase, or both, many studies reported only 
the total BPA concentration, that is, uncon-
jugated plus conjugated BPA. Of the seven 
studies that specifically examined unconju-
gated BPA, six detected unconjugated BPA 
in at least one sample (Calafat et al. 2009; 
Kim et al. 2003; Ouichi and Watanabe 2002; 
Schöringhumer and Cichna-Markl 2007; 
Volkel et al. 2008; Ye et al. 2005b); only one 
study failed to detect unconjugated BPA in 
any sample (Brock et al. 2001). The distinc-
tion between conjugated and unconjugated 
BPA is an important one, especially in blood 
samples, where the presence of unconjugated 
BPA in circulation indicates internal expo-
sure to the parent compound, which is estro-
genically active. The presence of unconjugated 
BPA in urine is also indicative of internal 
exposure to BPA and suggests either a failure 
of first-pass metabolism to conjugate and rap-
idly remove BPA from the body or the decon-
jugation of BPA metabolites in the body. It is 
also possible that these repeated measurements 
of unconjugated BPA in urine are the result 
of non  enzymatic deconjugation of conjugated 
BPA during storage, although storage proto-
cols provided in these studies and its repeated 
detection suggest that this is unlikely.
In contrast to the many small studies 
detecting BPA and/or its conjugates in urine, 
one study failed to detect either unconjugated 
or conjugated BPA in the 19 samples exam-
ined (Volkel et al. 2005). To our knowledge, 
this is the only published study that com-
pletely failed to detect or measure any form 
of BPA in urine samples from environmen-
tally exposed individuals. Volkel et al. (2005) 
used HPLC-MS/MS; this is the same tech-
nique that was used in several other studies 
in which unconjugated and conjugated BPA 
were detected in urine (Calafat et al. 2008; 
Hong et al. 2009; Mahalingaiah et al. 2008; 
Nepomnaschy et al. 2009; Teitelbaum et al. 
2008; Wolff et al. 2007; Yang YJ et al. 2009; 
Ye et al. 2009a). Why did Volkel et al. (2005) 
not detect any form of BPA? The first pos-
sibility to consider is whether their study was 
the only one that successfully avoided external 
contamination of samples with BPA. Because 
several of these bio  monitoring studies were 
performed by high-standard analytical labo-
ratories (e.g., CDC), it is unlikely that all of 
these studies except the one by Volkel et al. 
(2005) failed to adequately prevent external 
contaminations (Ginsberg and Rice 2009). 
The second possibility to consider is whether 
Volkel et al. (2005) used a method with suf-
ficient sensitivity to detect any form of BPA 
in urine. Unlike the other studies using 
HPLC-MS/MS, which is generally a very 
sensitive method (LODs ≤ 0.4 ng/mL), the 
LOD of Volkel et al.’s study was 1.14 ng/mL. 
Two other studies used analytical methods 
with similar or higher LODs: Matsumoto 
et al. (2003) used HPLC and detected total 
BPA in most of the 106 individuals examined 
(LOD = 1.7 ng/mL), and Mao et al. (2004) 
used HPLC with fluorescence detection and 
found total BPA in most of the 20 individuals 
examined (LOD = 2.7 ng/mL). In addition, 
considering the mean (or median) concentra-
tions of total BPA detected in other studies 
examining urine samples with HPLC-MS/MS 
[2.0 ng/mL (Wolff et al. 2007); 2.6 ng/mL 
(Calafat et al. 2008); 1.3 ng/mL (Mahalingaiah 
et al. 2008); 2.7 ng/mL (Hong et al. 2009); 
1.82 ng/mL (Nepomnaschy et al. 2009); 
0.52–0.61 ng/mL (Yang YJ et al. 2009); 2.52–
4.50 ng/mL (Ye et al. 2009a)], this less sensi-
tive analytical method would likely be able 
to detect some form of BPA in the average 
person. To address the issue of whether their 
experimental system was able to detect BPA at 
all in urine samples, Volkel et al. (2005) spiked 
urine samples with large amounts of BPA 
glucuronide. Under these conditions, they Vandenberg et al.
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were able to successfully detect this compound 
using their methodology, suggesting that there 
were no problems detecting high concentra-
tions of BPA metabolites in urine. Considering 
that this study examined < 20 adults, the nega-
tive result reported by Volkel et al. (2005) 
could be explained as a sampling error com-
bined with a relatively insensitive analytical 
method, but this is unlikely, leaving us with no 
scientific explanation for their lack of detection 
of BPA. Because science is based on repeatabil-
ity of data, the fact that this one negative study 
stands against more than a dozen studies that 
successfully measured BPA in urine samples 
suggests that it is an outlier.
The smaller studies described above pro-
vide little information about exposure of the 
general population. In 2005, the first study to 
measure total BPA concentrations in a refer-
ence population was performed by the CDC 
(Calafat et al. 2005); total BPA was detected 
in 95% of spot urine samples collected from 
394 American adults. The CDC followed this 
study with a second one, examining spot urine 
samples from 2,517 Americans > 6 years of 
age from the 2003–2004 National Health and 
Nutrition Examination Survey (NHANES) 
(Calafat et al. 2008). Total BPA was detected 
in 92.6% of participants, with concentrations 
ranging from 0.4 to 149 ng/mL and a geomet-
ric mean (GM) of 2.6 ng/mL urine.
Urinary volume is influenced by various 
factors (i.e., glomerular filtration, tubular secre-
tion and reabsorption, alimentary regimen, 
intake of liquids, perspiration) that give rise to 
differing urinary dilutions and, consequently, 
to changes in the concentrations of excreted 
substances (Carrieri et al. 2000). Dilute or 
concentrated samples provide low or high 
values, respectively, of the biological marker, 
with under  estimation or over  estimation of the 
result. Therefore, to compare exposures among 
groups of individuals, urinary concentrations 
of chemi  cals must be adjusted to urinary crea-
tinine concentration (Barr et al. 2005). After 
correcting for urine creatinine concentration, 
Calafat et al. (2008) found that total urinary 
BPA concentrations were associated with age, 
sex, race/ethnicity, and household income.
Four additional studies examined fairly 
large populations of adults. In a study of 
Table 1. BPA levels in human urine after environmental exposures.
Reference
Detection method 
and enzymatic LOD
Sample size Study population Detection rate
BPA level  
[ng/mL (ppb), mean ± SE]
treatmenta  (ng/mL) Unconjugated BPA Total BPA
Brock et al. 2001 GC-MSb  0.12 Five pools Each pool contained 
≥ 5 individuals
5/5 pools All < LOD Range, 0.11–0.51
Ouchi and Watanabe 2002 HPLC-ECD with 
column switchingb 
0.2 48 Female college students (Japan) 2% unconjugated 
BPA, 100% BPA 
glucuronide
Range, ND–0.2c 
Kim et al. 2003 RP-HPLC–FD 0.28 15 Korean males 100% unconjugated 
and total BPA
0.58 ± 0.14c,d  2.82 ± 0.73
15 Korean females 0.56 ± 0.10c,d  2.76 ± 0.54
Matsumoto et al. 2003 HPLC 1.7 50 College students in 1992 82% Exact values NR
56 College students in 1999 61% Exact values NR
Tsukioka et al. 2003 NCI–GC-MSb  0.1 6 Japanese adults 100% Mean, 1.6
Yang et al. 2003 HPLC-FDb  0.012 73 Koreans with various SULT1A1 
polymorphisms
75% Mean, ~ 9.5
Arakawa et al. 2004 GC-MS/MSb  0.38 36 Japanese males 100% Range, 0.2–14 
(µg/day)
Mao et al. 2004 HPLC-FDe  2.7 10 Chinese males 60% Range, ND–395
10 Chinese females 100% Range, 3–374
Calafat et al. 2005 GC-MSb  0.1 184 American males 96% GM, 1.63 
210 American females 94% GM, 1.12 
Kawaguichi et al. 2005 SBSE–GC-MS 0.02 5 Adult volunteers 80% Range, ND–5.41
Liu et al. 2005 HPLC with ECDb  0.5 9 American girls, 9 years of age 89% Median, 2.4
      24 American adults 52%   Median, 0.47
Volkel et al. 2005 HPLC-MS/MSb  1.14 6 German adults 0% —c  < LOD
Ye et al. 2005a Online SPE-
HPLC-MS/MS
0.4 30 American adults 87% GM, 3.5 
Ye et al. 2005b Online SPE-
HPLC-MS/MS
0.3 30 American adults 97% Mean, < LODc,d  Mean, 3.2 
Martin et al. 2005 SPE-HPLC-MS/
MSb 
NR 19 Children before dental 
treatment, ages not given
NR GM, 0.26
Joskow et al. 2006 GC-MSb  0.1 14 Men before dental treatment NR 2.41 ± 0.33 
Yang et al. 2006 HPLC-FDb  0.026 172 Koreans with various SULT1A1 
polymorphisms
97.5%   Median, 7.86
Moors et al. 2007 GC-MS 3 15 German adults 60% Range, ND–55
Schöringhumer and 
Cichna-Markl 2007
SGIC-HPLC-FD 0.2 12 Austrian adults 75% unconjugated 
BPA, 100% total
Median, 0.3 Median, 1.1
10 Dialysis patients (Austria) 90% unconjugated 
BPA, 100% total
Median, 0.2 Median, 1.2
Wolff et al. 2007 HPLC-MS/MSb  0.36 90 American girls, 6–9 years of age 94% GM, 2.0 
Calafat et al. 2008 HPLC-MS/MS 0.4 314 Children, 6–11 years of age 92.6% of all 
individuals examined
GM, 4.3 
713 Adolescents, 12–19 years of age GM, 2.8 
950 Adults, 20–59 years of age GM, 2.4 
537 Adults ≥ 60 years of age GM, 2.3 
García-Prieto et al. 2008 CME-LC-FDb  0.197 8 Spanish college students 25% unconjugated 
BPA, 100% total
Range, 4.03–49
continued next pageBiomonitoring suggests widespread BPA exposure
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172 Korean adults, Yang et al. (2006) found 
that 97.5% had detectable levels of total BPA, 
and in a study of 516 Korean adults, Hong 
et al. (2009) found detectable levels of total 
BPA in 76%. Yang YJ et al. (2009) exam-
ined urine from 485 Korean adults (259 men, 
92 pre  menopausal women, and 134 post-
menopausal women) and found detectable 
levels of total BPA in 76%, a strikingly similar 
result. In the fourth study, Volkel et al. (2008) 
examined 438 urine samples from 285 indi-
viduals, as well as additional samples collected 
from members of the research team; some 
of the samples examined had been stored for 
several years at –20°C. Because of problems 
with methodology, total BPA could only be 
meas  ured in a subset of the samples; total 
BPA concentrations ranged from undetected 
levels to 9.3 ng/mL. In sum, these six large-
scale studies (Calafat et al. 2005, 2008; Hong 
et al. 2009; Volkel et al. 2008; Yang et al. 
2006; Yang YJ et al. 2009) reinforce findings 
from small studies, providing further evidence 
that most individuals in several countries have 
detectable levels of BPA and/or its conjugates 
in their urine (Table 1).
Levels of BPA exposure and concentra-
tions in bodily fluids and tissues from indi-
viduals in less developed countries have been 
relatively under  studied and were previously 
identified as an important research need 
(Vandenberg et al. 2007). In a recent study in 
China, He et al. (2009) addressed this issue by 
examining > 900 human subjects. Detectable 
levels of total BPA were measured in 50% of 
the subjects. With this large sample size, the 
authors were able to detect several statistically 
significant associations: Detection rates were 
higher in males, in people > 40 years of age, in 
people with more education, and in individu-
als who smoked and/or consumed alcohol. 
Some of these results differ from the CDC’s 
findings in the United States (i.e., sex- and 
age-related differences in exposure) and thus 
may suggest that exposure routes or sources 
are different between these populations. 
Biomonitoring measurements for adults 
are generally not informative about internal 
Table 1. continued
Reference
Detection method 
and enzymatic LOD
Sample size Study population Detection rate
BPA level  
[ng/mL (ppb), mean ± SE]
treatmenta  (ng/mL) Unconjugated BPA Total BPA
Mahalingaiah et al. 2008 HPLC-MS/MS 0.4 45 Women in a fertility clinic 87% of all samples Range, ND–42.6; 
GM, 1.09 
37 Men in a fertility clinic Range, ND–18.7;
GM, 1.62 
Teitelbaum et al. 2008 HPLC-MS/MS 0.36 159 samples from 
35 children
American children, 6–10 years 
of age
95% GM, 3.4 
Volkel et al. 2008 Online SPE-
HPLC-MS/MSb 
0.3 31 German women NR for any samples 
or groups
ND–2.5 ND–6.5
30 German children, 5–6 years 
of age
ND–0.9 ND–7.5
315 samples from 
203 subjects
Archived samples collected from 
adults (2005)
All < LOQ (5 ng/mL) NR
62 samples from 
21 subjects
Laboratory workers (Germany) ND–1.8 ND–3.3
Wolff et al. 2008 Online SPE-
HPLC-MS/MS
0.36 404 Pregnant American women  90.8% Range, ND–35.2
Ye et al. 2008b  GC-MS/MSb  0.26 100 Pregnant Dutch women  82% Median, 1.2
Becker et al. 2009 LC/LC-MS/MS 0.25 137 German children, 3–5 years 
of age
99% of all samples 
> LOQ
GM, 3.55 
145 German children, 6–8 years 
of age
GM, 2.72 
149 German children, 9–11 years 
of age
GM, 2.22 
168 German adolescents, 12–14 
years of age
GM, 2.42 
Calafat et al. 2009 Online SPE-
HPLC-MS/MS
0.4 41g  Premature American infants  92% unconjugated 
BPA, 100% total
Range, ND–17.3; 
median, 1.7
Range, 1.6–946; 
median 28.6,
GM, 1.8  GM, 30.3 
Carwile et al. 2009 Online SPE-
HPLC-MS/MS
0.4 77 American college students 
avoiding polycarbonate bottles
88% GM, 1.3 
Same students using 
polycarbonate bottles
96% GM, 2.1 
He et al. 2009 HPLCb  0.31 419 Chinese males 58% GM, 1.41 
503 Chinese females 44% GM, 0.58 
Hong et al. 2009 HPLC-MS/MS 0.063 516 Korean adults 76% 2.742 ± 0.39
Nepomnaschy et al. 2009 HPLC-MS/MSb  0.18 60 Premenopausal women 100% 1.82 ± 0.33
Yang YJ et al. 2009 HPLC-MS/MS 0.0063 259 Korean men 75% GM, 0.52 
92 Premenopausal Korean women 80% GM, 0.61 
134 Postmenopausal Korean women  75% GM, 0.58 
Ye et al. 2009a  HPLC-MS/MS 0.26 10 pools Pregnant Norwegian women, 
110 total
NR for any samples 
or groups
GM, 4.50 
110 Pregnant Dutch women GM, 2.52 
87 Pregnant American women GM, 3.93 
Abbreviations: CME, coacervative microextraction; ECD, electron capture detection; FD, fluoremetric detection; GM, geometric mean; LOQ, limit of quantification; NCI, negative chemi-
cal ionization; ND, not detected; NR, not reported; RP, reverse phase; SBSE, stir bar sorptive extraction; SGIC, sol-gel immunoaffinity column; SPE, solid-phase extraction; SULT1A1, 
sulfotransferase 1A1 gene. 
aAll samples were treated with glucuronidase and sulfatase unless otherwise noted. bSamples were treated with glucuronidase only. cBPA glucuronide was also measured. dBPA 
sulfate was also measured. eSamples were treated with chemical hydrolysis, which deconjugates both sulfate and glucuronide groups. fCorrected for creatinine and presented as µg/g 
creatinine. gOnly 37 samples were tested for unconjugated BPA. Vandenberg et al.
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concentrations or exposure levels in children. 
The CDC study (Calafat et al. 2008) exam-
ined total BPA content in spot urine sam-
ples from 314 American children 6–11 years 
of age and reported a GM concentration of 
3.6 ng/mL urine. The GM level of total BPA 
in the 715 adolescents 12–19 years of age 
examined in the same study was 3.7 ng/mL 
urine. When adjusted for creatinine levels, 
exposures were highest in children and still sig-
nificantly higher in adolescents than in adults. 
Six additional studies measured BPA and its 
metabolites in urine of infants and children. 
Liu et al. (2005) examined urine from nine 
9-year-old American girls and detected total 
BPA in eight of the girls. Wolff et al. (2007) 
detected total BPA in 94% of urine samples 
collected from 90 American girls 6–9 years of 
age. In another study, Teitelbaum et al. (2008) 
examined 159 urine samples that had been col-
lected from 35 black and Hispanic American 
children 6–10 years of age; of these spot urine 
samples, 95% had detectable concentrations of 
total BPA, with a GM of 3.4 ng/mL urine, a 
level very similar to those of children examined 
in the larger CDC study (Calafat et al. 2008). 
In a large study that included a subset of 
30 German children 5–6 years of age, Volkel 
et al. (2008) meas  ured unconjugated BPA 
concentrations up to 0.9 ng/mL and total BPA 
concentrations up to 7.5 ng/mL, although the 
frequency of detection was not reported. In a 
study of 599 German children 3–14 years of 
age, Becker et al. (2009) detected total BPA 
in the urine of 591 individuals (98.7%; GM 
of 2.66 ng/mL); they detected significantly 
higher levels in children 3–5 years of age 
(GM, 3.55; n = 137). Finally, Calafat et al. 
(2009) studied 41 premature infants in an 
American neonatal infant care unit and found 
BPA conjugates in the urine of all the babies 
examined. Amazingly, the GM concentra-
tions measured in these infants were 11 times 
higher than the concentrations measured in 
the NHANES study (30.3 vs. 2.6 ng/mL 
urine). Unconjugated BPA was also detected 
in the urine of 34 of the 37 neonates exam-
ined, with a GM of 1.8 ng/mL urine (Calafat 
et al. 2009). These authors noted that the 
presence of unconjugated BPA in urine was 
unexpected, and because of the collection of 
urine from cotton placed in diapers, there is 
uncertainty as to whether this is a contaminant 
from the collection process or a true meas-
ure of unconjugated BPA from these young 
individuals. Collectively, these seven studies 
included 41 premature infants (Calafat et al. 
2009), 909 children 3–11 years of age (Becker 
et al. 2009; Calafat et al. 2008; Liu et al. 
2005; Teitelbaum et al. 2008; Volkel et al. 
2008; Wolff et al. 2007), and 883 adolescents 
12–19 years of age (Becker et al. 2009; Calafat 
et al. 2008) and repeatedly found detectable 
levels of total BPA in a vast majority of the 
individuals examined. These studies clearly 
indicate that children are exposed to BPA and 
suggest that exposures are highest among neo-
nates and young children.
Four studies examined total BPA concen-
trations in urine collected from women dur-
ing pregnancy, further suggesting exposure of 
the fetus to BPA during gestation (Table 1). 
First, in a study examining spot urine samples 
collected from 100 pregnant Dutch women, 
Ye et al. (2008b) detected total BPA in 82% 
of samples, with a median concentration of 
1.2 ng/mL urine, similar to the levels of BPA 
detected in other populations, including U.S. 
reference populations (Calafat et al. 2005, 
2008). An even larger study examined urine 
from 404 American women in their third 
trimester of pregnancy. In that study Wolff 
et al. (2008) detected total BPA in the urine 
of 90.8% of the women, and urine concen-
trations were associated with offspring birth 
weight. A third study examined total BPA 
in 10 pooled urine samples from 110 preg-
nant Norwegian women (Ye et al. 2009a); 
the concentrations measured were higher 
than in any other study of pregnant women 
(mean, 4.5 ng/mL). These authors also exam-
ined urine samples from 110 pregnant Dutch 
women and 87 pregnant American women. 
The concentrations in these populations were 
relatively high compared with other groups 
that have been examined, with mean con-
centrations of 2.52 and 3.93 ng/mL, respec-
tively (Ye et al. 2009a). In the final study to 
include urine samples from pregnant women 
(Mahalingaiah et al. 2008), samples were col-
lected from a fertility center in Massachusetts. 
In urine samples collected from 45 women 
before pregnancy, the GM concentration of 
total BPA was 1.09 ng/mL urine. During the 
study period, 10 subjects became pregnant. 
In these women, total BPA concentrations in 
their urine were 26% higher than in urine of 
non  pregnant women and 33% higher than 
in urine samples collected before pregnancy. 
This last finding is perhaps the most concern-
ing indicator of exposure of the human fetus 
to BPA.
Other studies have estimated associations 
between BPA concentrations and activities 
that may increase BPA exposure. For example, 
Matsumoto et al. (2003) associated the urinary 
concentrations of Japanese subjects with their 
consumption of coffee and tea drinks from 
cans containing BPA resins. Interestingly, 
when can coatings were changed to a formula 
with a lower BPA content, the association 
they found was no longer evident; in addi-
tion, removal of BPA from can linings led to a 
> 50% reduction in conjugated BPA detected 
in urine. Carwile et al. (2009) meas  ured total 
BPA concentrations in urine collected from 
a group of American college students dur-
ing a wash  out phase when all cold beverages 
were consumed from stainless steel contain-
ers, and compared these concentrations with 
those from the same students during a phase 
when all cold beverages were consumed from 
polycarbonate plastic containers. The authors 
found that urinary concentrations of total BPA 
were increased significantly (69% higher) dur-
ing the week when poly  carbonate bottles were 
used, suggesting that these containers may be a 
significant source of BPA exposure to individ-
uals in this age group and that interventions 
would help lower exposure levels. Joskow et al. 
(2006) made an interesting observation about 
urinary concentrations of total BPA in male 
volun  teers receiving dental sealant treatments: 
Compared with baseline levels (2.41 ng/mL), 
individuals who received one brand of sealant 
known to contain BPA had significantly more 
BPA metabolites in their urine 24 hr after seal-
ant placement (7.34 ng/mL), whereas indi-
viduals who received a different sealant had 
concentrations similar to the pretreatment level 
(2.06 ng/mL) (Joskow et al. 2006). Another 
brief study examined total BPA in urine sam-
ples collected from American children before 
and after placement of dental sealants (Martin 
et al. 2005). Total BPA levels increased rap-
idly from baseline levels (0.26 ng/mL) within 
24 hr of sealant placement (1.18 ng/mL) and 
peaked 7 days after placement (1.21 ng/mL). 
However, the measured concentrations did 
not return to baseline 14 days after place-
ment (0.73 ng/mL), suggesting that exposure 
of children to BPA from dental sealants may 
be more than the acute exposure that has 
been suspected. Finally, Schöringhumer and 
Cichna-Markl (2007) compared urinary con-
centrations of unconjugated and total BPA in 
10 dialysis patients and 12 healthy adults but 
found no significant differences between these 
two groups. 
Estimates of BPA Consumption 
from Urinary Measures
Only a few studies have estimated total BPA 
exposure in the human population. Using 
exposure estimates from a variety of environ-
mental sources (i.e., water, air, and soil) and 
from food and beverage contamination (i.e., 
leaching rates from plastic containers and can 
linings), several studies estimated daily human 
intake of < 1 µg/kg body weight (BW)/day 
(Kang et al. 2006; Wilson et al. 2003, 2007). 
Additional studies have estimated daily 
BPA exposure by calculating BPA ingestion 
from food sources (European Union 2002). 
Biomonitoring data provide more reliable 
information about exposures because they do 
not require all the sources of exposure to be 
identified. This is especially important for the 
case of BPA, where non-oral routes of expo-
sure are suspected and the totality of sources 
has not yet been identified (Stahlhut et al. 
2009; Welshons et al. 2006).Biomonitoring suggests widespread BPA exposure
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Using toxicokinetics, urinary BPA   levels 
have been extrapolated to estimate daily 
intake levels. For instance, using urine sam-
ples collected from 48 women, Ouichi and 
Watanabe (2002) estimated daily intake to be 
0.6–71.4 µg/day. Using backward calculations 
from urinary BPA concentrations detected 
in Japanese adults, worst-case–scenario daily 
intakes for that popu  lation were estimated 
at 0.037–0.064 µg/kg BW/day for males 
and 0.043–0.075 µg/kg BW/day for females 
(Miyamoto and Kotake 2006). Kamrin 
(2004) utilized urine concentrations reported 
in two previous studies (Arakawa et al. 2004; 
Brock et al. 2001) to calculate daily intake 
levels of 0.002–0.3 µg/kg BW/day. Although 
these calculations and estimates have provided 
a range of doses that researchers can target 
for experimental animal studies, these figures 
were determined based on toxico  kinetic mod-
els that may be flawed, a topic that we discuss 
in further detail below.
Salivary Measures of BPA
Like urine, saliva is a preferred bodily fluid for 
biomonitoring purposes because collection 
requires relatively non  invasive procedures. 
To date, studies that have examined saliva 
for BPA have focused on the effects of dental 
sealant application to BPA concentrations. 
Since the 1960s, BPA diglycidyl methacrylate 
has been used as a component of many dental 
restorative materials, including those used for 
sealing molars.
Six studies have measured BPA in saliva 
after dental sealant application, and all were 
able to detect BPA in the saliva of some of 
the individuals examined (Arenholt-Bindslev 
et al. 1999; Fung et al. 2000; Joskow et al. 
2006; Olea et al. 1996; Sasaki et al. 2005; 
Zafra et al. 2002) (Table 2). These studies used 
different analytical methods and examined 
saliva collected at different points after sealant 
application. Although these studies provide 
interesting information about the dynamics of 
BPA leaching from sealants shortly after seal-
ant placement (Vandenberg et al. 2007), they 
are less informative about the use of saliva as 
a matrix for biomonitoring of BPA. Joskow 
et al. (2006) measured BPA concentrations 
in saliva before any treatment, with a mean 
level of 0.3 ng/mL saliva; this concentration 
is much lower than that measured in urine 
(Table 1). Owing to the possibility of con-
tamination with BPA leaching from dental 
materials, saliva does not seem to be a reliable 
biomonitoring tool for estimating systemic 
exposure to unconjugated BPA.
Internal Dosage Assessment 
from Blood Measures of BPA
Seventeen studies have measured BPA in blood 
and serum samples from healthy male and 
non  pregnant female adults (Dirtu et al. 2008; 
Fung et al. 2000; He et al. 2009; Hiroi et al. 
2004; Ikezuki et al. 2002; Inoue et al. 2000, 
2001; Kaddar et al. 2009; Kuroda et al. 2003; 
Liu et al. 2007; Sajiki et al. 1999; Sugiura-
Ogasawara et al. 2005; Takeuchi and Tsutsumi 
2002; Takeuchi et al. 2004; Volkel et al. 2005; 
Yang M et al. 2009; Yoshimura et al. 2002) 
(Table 3). Of these studies, five used ELISA, 
one used a radio  immunoassay (RIA), and the 
remainder used analytical chemistry to assess 
BPA concentrations. These studies had similar 
LODs compared with studies of urine, but 
unlike most urine studies, measurements per-
formed on blood, serum, or plasma samples 
usually measured unconjugated BPA specifi-
cally. In healthy, non  pregnant adults, uncon-
jugated BPA was detected in 14 of 16 studies 
(including 8 of 10 studies using analytical 
chemistry). Compared with the magnitude of 
studies examining BPA levels in urine, most 
of these studies involved smaller sample sizes. 
Large-scale biomonitoring studies measuring 
circulating levels of unconjugated BPA, an 
index of internal exposure levels, remain to be 
done, particularly in the United States; only 
two studies to date examined > 100 individu-
als, and neither of these included samples from 
Americans. However, of those studies that 
used analytical chemistry methods and meas-
ured detectable levels of BPA, mean concen-
trations were typically in the range of 1 ng/mL 
blood. These concentrations are quite similar 
to those reported for BPA conjugates in urine 
(Table 1) and clearly indicate that humans are 
internally exposed to unconjugated BPA.
In one of the larger studies of human 
blood, Kaddar et al. (2009) examined plasma 
samples from 207 individuals, collected ran-
domly in a French hospital, using an RIA 
(LOD = 0.08 ng/mL plasma; correlation with 
HPLC-MS, r2 = 0.92). Unconjugated BPA 
was detected in 83% of the samples, and 12% 
had > 2 ng/mL plasma. Patients undergoing 
dialysis were also examined in this study, and 
> 70% of patients had meas  urable concen-
trations of unconjugated BPA > 10 ng/mL 
plasma. In another recent study performed in 
China, He et al. (2009) measured total BPA 
concentrations in > 900 individuals. Because 
samples were treated with β-glucuronidase, 
it is impossible to determine the proportion 
of conjugated and unconjugated BPA that 
was present. Measurable levels of total BPA 
were found in 17% of the samples; detec-
tion levels were significantly higher in females 
than in males and in people < 40 years of 
age compared with people > 40 years of age, 
and were highest in individuals who smoked 
and/or consumed alcohol. Finally, a study 
examining stored blood samples collected 
from Korean women during 1994–1997 
measured both unconjugated and total BPA 
Table 2. BPA levels in saliva.
Reference
Detection 
method
LOD 
(ng/mL)
Sample 
size Sample End point(s) Leaching level (µg/mL)
Olea et al. 1996 HPLC (verified 
by GC-MS)
NR 18 Patients with 50 mg of sealant applied 
to a total of 12 molars
Saliva 1 hr after application Range, 3.3–30
Arenholt-Bindslev 
et al. 1999
HPLC 100 8 Patients with a total of 38 mg of sealant 
applied to a total of 4 molars
Saliva immediately after application Range, ND–2.8; mean, 1.43
      Saliva 1 hr after application Undetected in any sample
      Saliva 24 hr after application Undetected in any sample
Fung et al. 2000 HPLC-FD 5 22 Patients with 32 mg of sealants applied 
to a total of 4 molars
Saliva 1–3 hr after application Range, 0.0058–0.1056
Zafra et al. 2002 GC-MS 3 8 Patients undergoing dental repairs Saliva 1 hr after application Range, 0.0153–0.0324
Sasaki et al. 2005 ELISA NR 21 Patients treated with one of nine resins Saliva immediately after application Range, 0.0210–0.0601
Saliva after application and gargling Range, 0.0016–0.0047
Joskow et al. 2006 GC-MS 0.1 14 Patients treated with one of two dental 
sealants (Delton and Helioseal)
Saliva before dental sealant application 0.00030 ± 0.000043a
Saliva immediately after Delton sealant 
application
0.0428 ± 0.01032
Saliva 1 hr after Delton sealant application 0.00786 ± 0.00424
Saliva immediately after Helioseal sealant 
application
0.00054 ± 0.00020
Saliva 1 hr after Helioseal sealant application 0.00021 ± 0.000013
Abbreviations: FD, fluoremetric detection; ND, not detected; NR, not reported. 
aValues are mean ± SE. Vandenberg et al.
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in > 150 individuals (Yang M et al. 2009). 
About half of these women were breast cancer 
patients, and the other half were age-matched 
controls. These authors found no associations 
between breast cancer status and BPA concen-
trations. Total BPA was detected in 50.8% of 
the samples. However, the levels of uncon-
jugated BPA in most samples were < LOD 
(0.012 ng/mL).
We are aware of only two studies that 
were unable to detect BPA in any individual 
samples of blood from adults (Fung et al. 
2000; Volkel et al. 2005). Fung et al. (2000) 
examined 40 adults before and after the appli-
cation of dental sealant materials containing 
BPA. This study had an LOD of 5 ng/mL; 
considering other studies that suggest expo-
sures are typically in the 1 ng/mL range, it is 
not surprising that this study was unable to 
detect BPA in blood. In the second study that 
did not detect BPA in the blood of healthy 
individuals, Volkel et al. (2005) used LC-MS/
MS, typically a highly sensitive method, but 
examined only 19 adults. The authors of that 
study reported multiple LODs for blood 
samples (0.57 and 1.14 ng/mL), although 
a later study from this group suggested that 
the LOD was 0.5 ng/mL blood (Dekant and 
Volkel 2008). That study, which examined 
only 19 adults, was the same one that was 
unable to detect any form of BPA in urine 
(Volkel et al. 2005), suggesting that it is hin-
dered by methodological problems.
Several studies that examined BPA con-
centrations in blood or serum from relatively 
healthy adults also measured BPA in individu-
als with diseases or health-related conditions. 
Two studies found women with polycystic 
ovarian syndrome (PCOS) had higher serum 
levels of BPA than did healthy control women 
(Takeuchi and Tsutsumi 2002; Takeuchi et al. 
2004). These studies also found a positive asso-
ciation between serum testosterone levels and 
BPA concentrations; this finding is especially 
interesting because it provides a potential basis 
Table 3. BPA levels in human serum/blood after environmental exposures (non  pregnant adults).
Reference Detection method LOD (ng/mL) Sample size Sample type Subject description
BPA levela  
(ng/mL, mean ± SE)
Other individuals 
examined
Sajiki et al. 1999 Electrochemical 
detection or 
MS-ESI
0.1–0.2 12 Serum Healthy Japanese women Range, 0–1.6;
0.33 ± 0.54
9 Healthy Japanese men Range 0.38–1.0; 
0.59 ± 0.21
Fung et al. 2000 HPLC-FD 5 40 Blood Healthy American volunteers 
before dental sealant 
application
ND Individuals after 
dental sealant 
applicationb 
Inoue et al. 2000 HPLC with 
electrochemical 
detection
0.01 in solvent 6 Serum Healthy Japanese adults Mean 0.32  
  Coulometric array 0.05 in serum    
Inoue et al. 2001 LC-MS 0.1 3 Blood or plasmac  Healthy Japanese adults ND–1.0
Ikezuki et al. 2002 ELISA 0.3 in serum 30 Serum Healthy Japanese women 2.0 ± 0.146 Pregnant women, 
fetusesd 
Takeuchi and 
Tsutsumi 2002
ELISA 0.3 in serum 11 Serum Healthy Japanese men 1.49 ± 0.11 Women with PCOSe
14 Serum Healthy Japanese women 0.64 ± 0.1
Yoshimura et al. 
2002
GC-MS with NCI 5 pg/mL 20 Pooled serum (≥ 5 
individuals per pool)
NR 0.54 ± 0.037
Kuroda et al. 2003 HPLC fluorescence 
derivation, column 
switching
0.04 21 Serum Sterile Japanese women 0.46 ± 0.044 Pregnant women, 
fetusesd 
Hiroi et al. 2004 ELISA 0.5 (from Kodaira 
et al. 2000) 
11 Serum Healthy Japanese women 2.5 ± 0.452 Women with 
endometrial 
hyperplasias and 
cancerf 
Takeuchi et al. 2004 ELISA 0.3 in serum 19 Serum Healthy Japanese women 0.71 ± 0.09 Women with 
obesity, PCOS, or 
bothg 
Sugiura-Ogasawara 
et al. 2005
ELISA 0.5 (from Kodaira 
et al. 2000)
32 Serum Healthy Japanese women 0.77 ± 0.067 Women with 
recurrent 
miscarriageh 
Volkel et al. 2005 LC-MS/MS 0.57–1.14 19 Plasma NR ND  
Liu et al. 2007 LC-DAD-MS 0.05 10 Serum Healthy Chinese adults ND–0.28
Dirtu et al. 2008 SPE-GC-ECNI-MS 0.003 7 Individual serum 
samples
Healthy Belgian adults 0.98 ± 1.09
14 Pooled serum 
samples
Healthy Belgian women 1.17 ± 1.09
He et al. 2009 HPLC 0.39 404 Serum Healthy Chinese men GM, 0.20 
482 Serum Healthy Chinese women GM, 0.16 
Kaddar et al. 2009 RIA 0.08 207 Plasma French hospital patients, 
unknown health status
ND to > 2, detected 
in 83%
Patients with regular 
dialysis treatmenti 
Yang M et al. 2009 HPLC-FD 0.012 82 Blood Healthy Korean women Median, 0.03  Breast cancer 
patientsj 
Abbreviations: DAD, photodiode array detection; ECNI, electron capture negative ionization; ESI, electrospray ionization; FD, fluorometric detection; GM. geometric mean; NCI, nega-
tive chemical ionization; NR, not reported; ND, not detected; SPE, solid-phase extraction.
aIn studies where two populations were compared, concentrations reported are for healthy controls only. bUnconjugated BPA was not detected after application of dental seal-
ants. cThe authors interchange “blood” and “plasma,” so it is difficult to determine which was actually assessed. dSee Table 4. eMean concentration in women with PCOS, 1.04 ± 0.1 
ng/mL. fMean concentration in women with simple endometrial hyperplasias (benign), 2.9 ± 0.632 ng/mL; women with complex endometrial hyperplasias (malignant potential), 1.4 ± 
0.133 ng/mL; women with postmenopausal endometrial cancer, 1.4 ± 0.189 ng/mL. gMean concentration in women with obesity (no PCOS), 1.04 ± 0.09 ng/mL; PCOS (no obesity), 1.05 ± 
0.10 ng/mL; obesity and PCOS, 1.07 ± 0.16 ng/mL. hMean concentration in women with recurrent miscarriage, 2.59 ± 0.780 ng/mL. iMean concentration not provided for dialysis patients; 
> 70% had > 10 ng/mL. jMedian concentration for breast cancer patients, 0.61 ng/mL. Biomonitoring suggests widespread BPA exposure
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for gender-biased exposures or metabolism of 
BPA (Takeuchi et al. 2006).
Because of concerns that BPA alters the 
development of rodents exposed during gesta-
tion, several human biomonitoring studies 
have focused on measuring BPA in serum 
from pregnant women, and in plasma, serum, 
and tissue from umbilical cords (Ikezuki et al. 
2002; Kuroda et al. 2003; Lee et al. 2008; 
Padmanabhan et al. 2008; Schönfelder et al. 
2002; Tan and Ali Mohd 2003; Todaka and 
Mori 2002; Yamada et al. 2002) (Tables 4 
and 5). Of the eight studies examining these 
populations, six used analytical chemistry and 
two used ELISA. Regardless of the method 
used for detection, every study was able to 
detect unconjugated BPA in at least some of 
the samples collected. Interestingly, the levels 
detected in pregnant women were typically 
higher than those reported for non  pregnant 
adults; several studies that used analytical 
chemistry to assess BPA concentrations meas-
ured mean concentrations in the blood or 
serum from pregnant women at > 4 ng/mL 
(Lee et al. 2008; Padmanabhan et al. 2008; 
Schönfelder et al. 2002). However, only two 
studies collected samples from pregnant and 
non  pregnant women and directly compared 
them using identical methods; one reported 
slightly lower levels in pregnant women 
Table 4. BPA levels in human serum and blood during pregnancy (maternal) or gestation (fetal).
Reference Detection method LOD (ng/mL)
Sample 
size Sample type Study population
BPA level  
[ng/mL (ppb), mean ± SE]
Ikezuki et al. 2002 ELISA 0.3 (serum) 37 Maternal seruma Japanese women in early pregnancy 1.5 ± 0.197
    37 Maternal serum Japanese women in late pregnancy 1.4 ± 0.148
    32 Fetal (cord) serum 2.2 ± 0.318
Schönfelder et al. 2002 Derivatization- GC/MS 0.01 (serum) 37 Fetal (cord) serum 2.9 ± 0.411
    37 Maternal serum German women at delivery 4.4 ± 0.641
Yamada et al. 2002 ELISA 0.5 200 Maternal serum Japanese women carrying fetuses 
with normal karyotypes
Median, 2.24 
    48 Maternal serum Japanese women carrying fetuses 
with abnormal karyotypes
Median, 2.97 
Kuroda et al. 2003 HPLC fluorescence  
derivation, column switching
0.04 9 Maternal seruma Japanese women at delivery 0.46 ± 0.067
9 Fetal cord serum 0.62 ± 0.043
Tan and Mohd 2003 GC-MS 0.05 180 Fetal cord plasma Samples collected in Malaysia Range, ND–4.05  
(88% with positive detection)
Lee et al. 2008 HPLC-GC-MS 0.625 300 Maternal blood Korean women at delivery 9.04 ± 0.81
Range, ND–66.48
300 Fetal (cord) blood 1.13 ± 0.08
Range, ND–8.86
Padmanabhan et al. 2008 HPLC-ESI-MS/MS 0.5 40 Maternal blood American women at delivery 5.9 ± 0.94  
Range, ND–22.3
Abbreviations: ESI, electrospray ionization; ND, not detected.
aData on non  pregnant females is included in Table 3. 
Table 5. BPA levels in human tissues and fluids during pregnancy and lactation.
Reference Detection method
LOD 
(ng/mL)
Sample 
size End point(s) Study population
BPA level 
[ng/mL (ppb), mean ± SE]
Ikezuki et al. 2002 ELISA 0.3 32 Early amniotic fluid (15–18 
weeks)
Pregnant Japanese women 8.3 ± 1.573
    38 Late amniotic fluid (at full term, 
before delivery)
Pregnant Japanese women 
undergoing cesarian section
1.1 ± 0.162
    36 Follicular fluid Japanese women undergoing 
IVF procedures
2.4 ± 0.133
Schönfelder et al. 2002 Derivatization- GC-MS 0.01 37 Placenta German women at delivery 11.2 ± 1.512 ng/g 
Todaka and Mori 2002 GC-MS NR NR Umbilical cord tissue at birth Samples collected in Japan Mean, 4.4 ± 1.5 ng/g; 
range, 0.11–15.2 ng/g 
Yamada et al. 2002 ELISA 0.5 200 Normal fetal amniotic fluid 
(14–18 weeks)
Pregnant Japanese women Median, 0.26; range, 
ND–5.62
    48 Abnormal fetal karyotype fetal 
amniotic fluid (14–18 weeks)
Pregnant Japanese women Median, 0 
Otaka et al. 2003 SPE-GC-MS 0.09 3 Breast milk Japanese women Range, ND–0.70 ng/g 
Sun et al. 2004 DIB-Cl derivatization-
HPLC
0.11 23 Breast milk Japanese women 0.61 ± 0.042
Engel et al. 2006 HPLC- electrochemical 
detection
0.5 21 Residual amniotic fluid from 
amniocentesis, < 20 weeks’ 
gestation
American women > 35 years 
of age
Mean, 0.55 
(10% > 0.5 ng/mL)
Ye et al. 2006 Online SPE-HPLC-MS/MS 0.28 20 Breast milk American women Unconjugated BPA: 
mean, 1.3; 60% detection
Total BPA: mean, 1.9; 
90% detection
Kuruto-Niwa et al. 2007 ELISA 0.3 101 Human colostrum Japanese women 3 days after 
delivery
3.41 ± 0.013
Ye et al. 2008a Online SPE-HPLC-MS/MS 0.3 4 Breast milk American women Unconjugated BPA: 
mean, 0.80
Total BPA: mean, 1.02
Kaddar et al. 2009 RIA 0.08 17 Follicular fluid French women undergoing IVF 
procedures
Range, ND–1.0; 39% 
detection
Abbreviations: DIB-Cl, 4-(4,5-diphenyl-1H-imidazol-2-yl)benzoyl chloride; ND, not detected; SPE, solid-phase extraction. Vandenberg et al.
1064  v o l u m e  118 | n u m b e r 8 | August 2010  •  Environmental Health Perspectives
(Ikezuki et al. 2002), and the other found no 
differences in these two populations (Kuroda 
et al. 2003). Thus, this is also an important 
area for future research.
Of the four studies that measured 
unconjugated BPA in umbilical cord blood 
(Table 4), two detected levels higher in fetal 
blood than in maternal samples (Ikezuki et al. 
2002; Kuroda et al. 2003), and two detected 
levels higher in maternal samples than in 
fetal blood (Lee et al. 2008; Schönfelder 
et al. 2002). Interestingly, two of these 
studies detected concentrations in a range 
(~ 1 ng/mL) similar to those meas  ured in 
healthy adults (Kuroda et al. 2003; Lee et al. 
2008). The other two studies measured BPA 
concentrations two to four times higher in 
fetuses than in non  pregnant women (Ikezuki 
et al. 2002; Schönfelder et al. 2002). As with 
the maternal blood samples, only two studies 
directly compared plasma/blood BPA con-
centrations in fetuses and non  pregnant adults 
(Ikezuki et al. 2002; Kuroda et al. 2003), so 
it is difficult to make any conclusive com-
parisons regarding internal concentrations, 
metabolism, or exposure.
With the exception of one recent study that 
measured BPA concentrations in the blood 
of 300 women and their fetuses (Lee et al. 
2008), the studies mentioned above are limited 
because of their relatively small sample sizes. 
This one large-scale study (Lee et al. 2008) is 
the most robust blood biomonitoring study of 
BPA to date. Despite the relatively high LOD 
(0.625 ng/mL) for the method used, total BPA 
was detected in the blood of 84% of pregnant 
women and 40% of fetal samples collected; 
23% of blood samples collected from pregnant 
women contained total BPA concentrations 
> 10 ng/mL, but concentrations of unconju-
gated BPA alone were not meas  ured. 
The overall consensus that can be deter-
mined from blood sampling of healthy adults, 
adults with certain diseases, pregnant women, 
and fetuses is that internal exposures to uncon-
jugated BPA are in the range of 0.5–10 ng/mL, 
with most studies suggesting an average inter-
nal exposure of approximately 1–3 ng/mL 
(Vandenberg et al. 2007). These concentra-
tions are higher than those required to stimu-
late responses in cell cultures (Wetherill et al. 
2007), suggesting that these low levels could 
influence biological end points and develop-
ment in humans (vom Saal et al. 2007). At 
this time, no information is available on BPA 
concentrations in the blood of infants after 
birth or of children and adolescents, indicating 
a significant data gap. Because neonates are 
not thought to have the metabolic enzymes 
to effectively conjugate BPA (Mykkanen et al. 
1997; Taylor et al. 2008), it is plausible and 
even likely that these individuals have higher 
concentrations of unconjugated BPA in their 
blood than do adults (de Wildt et al. 1999).
BPA Measurements  
in Amniotic Fluid, Placenta,  
and Follicular Fluid
Only a few studies have examined additional 
tissues and fluids associated with pregnancy 
(Table 5). In 2002, Schönfelder et al. (2002) 
measured unconjugated BPA concentrations 
in placental tissue from 37 pregnancies. BPA 
was detected in all samples, ranging from 
1.0 to 104.9 ng/g tissue, with a median value 
of 12.7 ng/g and a mean value of 11.2 ng/g. 
This study suggests that BPA is transplacen-
tally transferred to the embryo/fetal compart-
ment. Additional studies support the idea that 
the fetus is continuously exposed to BPA; 
three studies have demon  strated that it can be 
meas  ured in amniotic fluid (Engel et al. 2006; 
Ikezuki et al. 2002; Yamada et al. 2002). 
Ikezuki et al. (2002) found eight times higher 
concentrations of unconjugated BPA in amni-
otic fluid from early pregnancy compared 
with later pregnancy; they proposed that BPA 
may accumulate in early fetuses because of 
a lower metabolic clearance of BPA or may 
be conjugated more efficiently in the fetal 
liver during later gestation. In another study, 
Engel et al. (2006) detected unconjugated 
BPA in < 10% of the amniotic fluid samples 
collected from pregnancies before 20 weeks 
of gestation. Collectively, these studies lend 
support to the idea that the fetus is exposed to 
unconjugated BPA. In summary, additional 
studies using larger sample sizes, collection of 
samples controlled for BPA contamination, 
and sensitive methods of detection are needed 
to more accurately quantify BPA in amniotic 
fluid and placental tissue. However, published 
studies indicate that the fetus is likely exposed 
to unconjugated BPA via maternal uptake.
With an increase in the number of suc-
cessful pregnancies that have resulted from 
assisted reproductive technologies, two studies 
examining unconjugated BPA levels in fol-
licular fluid raise additional concerns (Ikezuki 
et al. 2002; Kaddar et al. 2009) (Table 5). 
First, Ikezuki et al. (2002) found an average 
concentration of 2.4 ng/mL fluid collected 
from women under  going in vitro fertiliza-
tion (IVF) procedures. Second, Kaddar et al. 
(2009) meas  ured BPA in follicular fluid from 
28 infertile women under  going IVF. The 
authors detected unconjugated BPA in 11 of 
these samples (39%) at concentrations that 
ranged from 0.15 to 1 ng/mL fluid. These 
studies have several limitations, including 
the analytical methods used and the selection 
of human subjects. However, studies from 
rodents suggest that BPA can cause aneu-
ploidy in oocytes (Susiarjo et al. 2007) and 
alter the body weight of offspring resulting 
from intra  uterine transplantation of embryos 
cultured in media containing BPA (Takai 
et al. 2001). As such, presence of meas  urable 
concentrations of unconjugated BPA in fol-
licular fluid is a potential concern.
BPA Exposure Assessment 
in Breast Milk
There is significant interest in defining all 
sources of BPA exposure, especially those 
specific to neonates, infants, and children; 
baby bottles and packaging of infant formu-
las are currently identified sources of oral 
BPA exposure (Gies et al. 2009; Vandenberg 
et al. 2007). An additional and important 
consideration for the health of the develop-
ing neonate is potential BPA exposure from 
breast milk. BPA is somewhat lipophilic [Kow 
(octanol–water partitioning coefficient) = 
2.2–3.4], allowing it to partition into fat and 
breast milk. Four small studies using ana-
lytical chemistry have measured BPA in the 
breast milk of healthy women (Table 5). The 
first study examined breast milk from three 
women and found detectable levels of uncon-
jugated BPA in two of the samples (Otaka 
et al. 2003). In another study, Sun et al. 
(2004) detected unconjugated BPA (range, 
0.28–0.97 ng/mL; mean, 0.61 ng/mL) in the 
breast milk of 100% of the women studied. 
A third study detected unconjugated BPA in 
60% of samples (mean, 1.3 ng/mL milk) and 
total BPA in 90% (mean, 1.1 ng/mL milk) 
(Ye et al. 2006). In the fourth study, Ye et al. 
(2008a) detected unconjugated and total BPA 
in all four of the samples examined. 
In a larger study, Kuruto-Niwa et al. 
(2007) examined BPA concentrations in 
human colostrum, the milk produced within 
the first 3 days after giving birth that contains 
high levels of anti  bodies, carbohydrates, and 
protein. Using ELISA, the authors reported 
detecting unconjugated BPA in 100% of the 
101 samples examined (range, 1–7 ng/mL 
colostrum; mean, 3.41 ng/mL). Although 
the sample sizes in these studies are relatively 
small, these findings highlight the concerns 
about exposure of human infants to BPA via 
breast milk in addition to other exposures 
from baby bottles and other containers.
BPA Exposure Assessment 
in Adipose Tissue
To address the potential for BPA to accumu-
late in adipose tissue, Fernandez et al. (2007) 
examined 20 adult women from Spain for 
both unconjugated BPA and chlorinated BPA 
derivatives. Chlorinated BPA derivatives are 
thought to form when BPA is conjugated 
in treated water sources. Fernandez et al. 
(2007) detected unconjugated BPA in 55% 
of the samples and Cl2BPA in 80% of sam-
ples; other chlorinated derivatives, including 
ClBPA and Cl3BPA, were detected less fre-
quently, and Cl4BPA was not detected in any 
sample. Of those samples in which BPA was 
detected, concentrations ranged from 1.80 to Biomonitoring suggests widespread BPA exposure
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12.01 ng/g adipose tissue (mean, 3.16 ng/g) 
(Fernandez et al. 2007). In another study, 
Nunez et al. (2001) reported that repeated 
exposure to relatively high BPA doses resulted 
in the distribution of BPA to bodily tissues 
in rats, including adipose tissue. Human 
biomonitoring studies using adipose tissue 
are understandably quite limited because of 
the invasive procedures needed to isolate this 
biological matrix, so it is not likely that this 
study will be repeated with a larger sample 
size or a broader population. However, it does 
point out that there are other metabolites of 
BPA that should be examined for biological 
and hormonal activity.
Relationships between 
Measured BPA Concentrations 
and Disease Outcomes
In 2008, a large and well-controlled study 
of the possible health effects of BPA expo-
sure on humans was conducted using sam-
ples and information collected for NHANES 
(Lang et al. 2008). By examining data from 
1,455 American adults, these authors found 
positive associations between urinary (total) 
BPA concentrations and the prevalence of 
diabetes, heart disease, and liver toxicity. In 
a recent study, Melzer et al. (2010) retested 
the originally identified associations between 
higher urinary total BPA concentrations 
and reported heart disease using a second 
NHANES database. Indeed, the authors were 
able to replicate earlier associations that were 
detected between higher urinary concentra-
tions of total BPA and an increased prevalence 
of coronary heart disease, even though urinary 
BPA concentrations in this second study were 
substantially lower than those measured in 
the first (Lang et al. 2008). In both of these 
studies, adult exposure levels were associated 
with chronic diseases that probably began 
much earlier in the individual’s life. Also of 
note is that, as with most epidemiological 
studies, it is impossible to determine cause-
and-effect relationships between meas  ured 
concentrations and disease states. Therefore, 
the authors cannot determine whether higher 
concentrations of BPA cause these conditions, 
or if the presence of these diseases leads to 
increased exposure or decreased metabolism 
of BPA; either of these situations is poten-
tially concerning. Additional studies are there-
fore needed to determine whether there is a 
causal link between elevated BPA concentra-
tions in urine and these chronic diseases. In 
addition, it should be noted that these stud-
ies used only single urine collections from 
the individuals examined (Lang et al. 2008; 
Melzer et al. 2010); multiple collections 
from individuals over a range of life stages, 
especially encompassing periods of organo-
genesis, would be more useful for determining   
causative   relationships.
Another recent study examined BPA con-
centrations in urine and blood collected from 
516 Korean adults living in urban areas (Hong 
et al. 2009). Urinary concentrations of total 
BPA were associated with at least one marker 
of oxidative stress, although these associations 
were no longer statistically significant when 
age, sex, weight, smoking, and exercise were 
considered in the regression models. Hong 
et al. (2009) also detected an association 
between high BPA exposures and increased 
fasting blood glucose levels, perhaps lending 
additional weight to a possible link between 
BPA exposure and diabetes. Another study 
supports the connection between BPA expo-
sure and oxidative stress; Yang YJ et al. (2009) 
found that total BPA levels were associated 
with markers of stress in post  menopausal 
women, but not in pre  menopausal women or 
men, leading the authors to suggest that post-
menopausal women may be more susceptible 
to BPA-induced adverse health effects. 
Several smaller studies have examined the 
effects of BPA exposure on other health out-
comes. For instance, BPA levels in blood have 
been associated with a variety of conditions in 
women, including obesity, endometrial hyper-
plasia, endometriosis, recurrent miscarriages, 
sterility, and PCOS (reviewed by Vandenberg 
et al. 2007). Other studies detected asso-
ciations between high BPA exposure and 
chromosomal abnormalities, including preg-
nancies with fetuses that had an abnormal 
karyotype (Yamada et al. 2002), recurrent 
miscarriage (Sugiura-Ogasawara et al. 2005), 
and sister chromatid exchange measured in 
peripheral lymphocytes (Yang et al. 2006). 
These epidemiological studies have several 
limitations, including small sample sizes, 
insufficient information on subject selection 
criteria, and cross-sectional designs that failed 
to adequately control for potential confound-
ers (Vandenberg et al. 2007), thus preventing 
accurate assessments regarding the potential 
health risks of BPA. Even more recent stud-
ies have identified relationships between BPA 
exposure and reproductive hormone levels in 
male patients at an infertility clinic (Meeker 
et al. 2010) and the number of oocytes 
retrieved from women undergoing IVF fertil-
ity treatments (Mok-Lin et al. 2009). Finally, 
prenatal BPA exposures, as determined by 
maternal urine concentration during preg-
nancy and at delivery, were found to be asso-
ciated with increased externalizing behaviors 
(i.e., aggression, hyper  activity), especially in 
female toddlers (Braun et al. 2009).
It is somewhat surprising that most stud-
ies undertaken to understand human health 
hazards have relied heavily on biomonitoring 
of BPA from the general population, and only 
a few studies have measured exposures to BPA 
in occupational settings or have associated 
occupational exposures with adverse health 
outcomes. This limitation may stem from the 
belief that BPA exposure comes predominantly 
from contamination via food sources. Despite 
reports suggesting exposure of healthy individ-
uals to BPA by non-oral routes (Stahlhut et al. 
2009), a data gap exists relative to exposure 
levels in employees in BPA-producing indus-
tries or those workers using BPA in different 
manufacturing processes. Thus, measurement 
strategies and studies to investigate occupa-
tional exposure to BPA and health outcomes 
are very much needed.
Reliability of Biomonitoring 
and Toxicokinetic Studies
The need for human biomonitoring of BPA 
for risk assessment purposes is undisputed 
because all sources of exposure have not been 
identified, and thus internal exposures can-
not be properly calculated. Groups charged 
with assessing risk from exposure have heated 
debates about the toxico  kinetics of BPA 
and the plausibility and reliability of indi-
vidual data and analytical approaches used in 
biomonitoring studies. Two studies thus far 
have attempted to determine the kinetics of 
BPA metabolism in human subjects (Volkel 
et al. 2002, 2005).
The first toxicokinetic study was designed 
to resolve issues regarding the internal expo-
sure to BPA that originated from animal 
studies: Volkel et al. (2002) administered 
5 mg deuterium-labeled BPA (equivalent to 
54–90 µg/kg BW) orally to adult volunteers 
and monitored blood and urinary BPA lev-
els. Unconjugated BPA was always < LODs 
in both plasma (LOD = 2.28 ng/mL) and 
urine (LOD = 1.37 ng/mL) at all time points 
studied after BPA administration; the results 
were interpreted by the authors as indicative 
of rapid metabolism, noting that “only a small 
percentage of the dose of [BPA] is available for 
other biotransformation pathways, due to the 
rapid glucuronidation” (Volkel et al. 2002). 
In support of this statement, concentrations 
of conjugated BPA were also measured in 
blood and urine; the authors reported that 
BPA glucuronide concentrations fell below 
the LOD in both urine and blood 24–34 hr 
after BPA adminis  tration, although this is not 
apparent from the concentration–time course 
model they presented. Using their finding that 
the terminal half-life of BPA glucuronide in 
blood was 5.3 hr, Volkel et al. (2002) con-
cluded that conjugated BPA is also rapidly 
cleared from the blood.
Several inconsistencies in the article by 
Volkel et al. (2002) raise questions about its 
reliability. For instance, the authors reported 
two different values for the time when maxi-
mal plasma concentrations (Cmax) were 
achieved (1.35 hr vs. 4 hr). In addition, the 
BPA glucuronide levels reported in blood 
are higher than the total BPA concentrations Vandenberg et al.
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measured in the same individuals. Finally, the 
authors indicated that they measured BPA 
metabolism in three women, a group of three 
men, and then in a separate group of four 
men, yet the groups of male volunteers clearly 
overlap (at least 2 men were subjects in both 
groups), making the data compiled from com-
bining these two groups questionable. 
In drawing their conclusion that there 
is no risk from current human exposure lev-
els, Volkel et al. (2002) overlooked several 
important points from a risk assessment per-
spective. First, they did not acknowledge the 
likelihood of different toxico  kinetics when 
BPA exposure is continuous compared with 
a single adminis  tration. Ginsberg and Rice 
(2009) suggested that results from the Volkel 
et al. (2002) study were more consistent with 
delayed excretion from long-term internal 
storage or cycling between conjugation and 
deconjugation. Second, the potential for BPA 
to have actions at low levels (in the nanograms 
per milliliter range) was not considered. Third, 
this toxico  kinetic study was designed to assess 
the metabolism of BPA after oral exposure 
because, until very recently (Stahlhut et al. 
2009), it was assumed that most if not all BPA 
exposure in humans occurs via the oral route. 
However, because all sources of BPA have not 
been identified, non-oral exposures cannot 
be discounted. Finally, Volkel et al. (2002) 
over  looked the possibility of differences in 
toxico  kinetics under different physiological 
paradigms; they used a small mixed-subject 
group composed of individuals of both sexes 
and different ages. The differences between 
sexes and age groups in urinary BPA levels 
found in CDC biomonitoring studies (Calafat 
et al. 2005, 2008) raise the possibility that 
the toxico  kinetics of chemicals and drugs, 
including BPA, are likely to be very differ-
ent in fetuses and neonates compared with 
adults. In fact, this assumption was confirmed 
in two independent kinetic models, which 
found that the internal exposure to BPA in 
newborns can be 3–10 times higher than in 
adults (Edginton and Ritter 2009; Mielke and 
Gundert-Remy 2009). There is also the poten-
tial for deconjugation of BPA glucuronide 
in utero by β-glucuronidase, an enzyme that 
is present in high concentrations in placenta 
and various other tissues (Ginsberg and Rice 
2009). Furthermore, studies in rodents have 
found that neonates have limited ability to 
convert BPA into an inactive conjugated form, 
independent of the route of administration 
(Taylor et al. 2008). This may also be true for 
human fetuses and neonates.
In a follow-up investigation, Volkel et al. 
(2005) further examined the kinetics of BPA 
in urine and plasma. They assessed BPA 
exposure both after adminis  tration of labeled 
BPA and in an environmentally exposed 
population. For direct testing, subjects were 
adminis  tered 25 µg labeled BPA (equivalent 
to 0.28–0.43 µg/kg BW), a much smaller 
dose than that administered in their earlier 
study; unconjugated and conjugated BPA 
were then measured in urine (Volkel et al. 
2005). Although the authors suggested that 
they had developed a very sensitive and selec-
tive method, the LODs for this study were 
again higher than those in other studies using 
the same analytical methods (for unconju-
gated BPA, LOD = 1.14 ng/mL; for BPA 
glucuronide, LOD = 10.1 ng/mL).
Volkel et al. (2005) examined BPA kinet-
ics in six individuals adminis  tered BPA, 
although they provided no information about 
the characteristics of these subjects, making it 
difficult to draw any conclusions from their 
study. The authors suggested that there were 
no differences in kinetics among volunteers, 
yet a closer look at their results shows a wide 
variation in BPA measurements across indi-
viduals. In the three men examined, 85% of 
the administered BPA dose was recovered in 
urine after 5 hr, mostly as BPA glucuronide. 
In the three women examined, 75% of BPA 
was recovered as BPA glucuronide after the 
same period of time. In two of six individuals, 
unconjugated BPA was detected at levels of 
approximately 1 ng/mL urine. This finding 
directly contradicts the conclusions reached 
by the study authors, who suggested that 
100% first-pass metabolism would promptly 
convert BPA to its conjugated metabolites. 
As mentioned above, several other stud-
ies have also detected unconjugated BPA in 
urine (Calafat et al. 2009; Kim et al. 2003; 
Ouichi and Watanabe 2002; Schöringhumer 
and Cichna-Markl 2007; Volkel et al. 2008; 
Ye et al. 2005b). Volkel et al. (2005) also 
collected plasma samples for measurement 
of BPA, although no measurements of con-
jugated or unconjugated BPA were reported. 
Finally, unlike other biomonitoring stud-
ies, these investigators failed to detect any 
BPA in the environmentally exposed group, 
likely because the LODs in these kinetic stud-
ies were 10 to 100 times less sensitive than 
methods used in most biomonitoring stud-
ies. These limited observations emphasize the 
need for risk assessment studies to employ 
state-of-the-art analytical techniques that are 
sensitive enough to detect low levels of BPA 
with large sample sizes so that one can con-
sider variability in the population and influ-
ence from physiological status; these kinetic 
studies therefore are not appropriate for risk 
assessment of BPA.
The next issue to consider is whether 
biomonitoring studies per se are sufficiently 
reliable and therefore useful for risk assess-
ment purposes. The detection rates and 
concentrations of BPA in urine and blood 
of environmentally exposed individuals are 
remarkably similar in studies performed by 
several independent groups using state-of-
the-art analytical techniques; independent 
confirmation of these results alone indicates 
that that these studies are reliable. These find-
ings are further supported by the dozens of 
additional studies that have used less sensitive 
or less selective methodologies, because all 
of these studies report conjugated or uncon-
jugated BPA levels in human samples in a 
very narrow range of concentrations. Taken 
together, although the discussions about the 
reliability of unconjugated BPA measure-
ments within human tissues and fluids appear 
to be ongoing, especially in the risk assess-
ment community, the consistency of available 
data on internal exposure to BPA across inves-
tigative groups is more than convincing.
Several biomonitoring studies (Calafat 
et al. 2005, 2008; Kim et al. 2003; Mao et al. 
2004) and one of the toxico  kinetic studies 
(Volkel et al. 2005) suggest that men and 
women differ in their uptake and/or metabo-
lism of BPA. Other studies suggest that preg-
nant and non  pregnant women differ in their 
uptake or metabolism of chemicals, includ-
ing BPA. These findings reinforce the fact 
that kinetic models based on metabolism of 
BPA from a mixed group of adults cannot be 
extrapolated to different physiological states, 
especially vulnerable populations such as preg-
nant women and children.
Utility of Physiologically Based 
Toxicokinetic Models of BPA
Physiologically based toxicokinetic (PBTK) 
modeling incorporates information on the 
physiology and anatomy of the experimental 
animal or human and the biochemistry of the 
chemical of interest into a conceptual model 
for computer simulation. Compared with the 
essentially empiric kinetic models (i.e., the so-
called classical kinetic models), PBTK model-
ing has the advantage of being more grounded 
in physiology. PBTK models are powerful 
tools for interpolations and extrapolations 
that are particularly useful in the context of 
risk assessment, such as dose to dose, route to 
route, single to multiple exposure, continuous 
to discontinuous exposure, species to species, 
“external” or administered dose and internal or 
target tissue concentration, males to females, 
adults to children, non  pregnant women to 
pregnant, and so on (Loizou et al. 2008).
A few PBTK models have been developed 
for describing the toxicokinetics of BPA in rats 
(Shin et al. 2004), pregnant mice (Kawamoto 
et al. 2007), adult humans (Teeguarden 
et al. 2005), and children < 2 years of age 
(Edginton and Ritter 2009). First, Shin et al. 
(2004) developed a PBTK model involving 
vein, artery, lung, liver, spleen, kidneys, heart, 
testes, muscle, brain, adipose tissue, and small 
intestines for predicting tissue distribution 
and kinetics of BPA in rats. The model was Biomonitoring suggests widespread BPA exposure
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validated by predicting the steady-state lev-
els of BPA in the blood and tissues of rats 
that had received repeated intra  venous injec-
tions. These investigators used their PBTK 
model to simulate blood and tissue levels of 
unconjugated BPA in an adult human (70 kg 
BW) receiving multiple oral doses of BPA 
(100 mg every 24 hr for 10 days) and found 
steady-state venous blood levels of 1.3 ng/mL, 
a concentration remarkably similar to what is 
measured in environmentally exposed humans 
(Table 3).
In a model of oral route exposure to BPA 
in rats and humans, Teeguarden et al. (2005) 
imposed restrictions on the concentration of 
unbound (free) BPA resulting from plasma 
protein binding and predicted the degree of 
ER binding that may occur in the rat uterus 
at different BPA doses. Based on simulations 
using the model, terminal BPA elimination 
in rats, but not humans, was found to be 
strongly influenced by the entero  hepatic recir-
culation of BPA glucuronide. The oral route 
blood kinetics in rats and the oral route plasma 
and urinary elimination kinetics in humans 
described by the model of Teeguarden et al. 
(2005) were consistent with data reported 
by Pottenger et al. (2000) and Volkel et al. 
(2002) for BPA-treated rats and human volun-
teers, respectively. However, their model was 
based on single exposures to BPA and did not 
account for repeated exposures to humans, as 
actually occurs. Nonetheless, as far as toxi-
cokinetic modeling in humans is concerned, 
plasma levels of unconjugated BPA predicted 
by the physiologically based pharmaco  kinetic 
(PBTK) model for a single oral dose of 5 mg 
BPA per person were less than the analytical 
LOD of the method used by Volkel et al. 
(2002). Thus, only appropriately sensitive 
analytical methods should be used to deter-
mine metabolic parameters after adminis-
tration of BPA.
More recently, a PBTK model was devel-
oped to assess the age dependence of the 
toxico  kinetics of both unconjugated BPA 
and BPA glucuronide in children < 2 years of 
age (Edginton and Ritter 2009). This PBTK 
model was initially built using information 
gathered from toxico  kinetic studies of BPA 
in adults and then scaled down taking into 
account the age dependence of physiological 
parameters relevant for absorption, distribu-
tion, metabolism, and elimination. According 
to the model predictions, steady-state plasma 
concentrations of unconjugated BPA in new-
borns were expected to be 11 times higher 
than those found in adults who received the 
same body weight–normalized dose. Taking 
into account estimates of dietary exposures, 
plasma levels of unconjugated BPA in 3- 
to 6-month-old children were expected to 
be 5 times higher than the levels found in 
adults. Simulations using this PBTK model 
are therefore consistent with the idea that 
newborns and young children are internally 
exposed to higher levels of unconjugated BPA 
than levels that have been estimated for adults. 
Indeed, data from infants in neo  natal infant 
care units in American hospitals suggested 
that BPA levels in these infants were 11 times 
higher than GM concentrations in American 
adults (Calafat et al. 2009), matching exactly 
the predictions from the PBTK model.
Another PBTK model—one for BPA in 
pregnant mice—was developed by Kawamoto 
et al. (2007). The authors used experimental 
kinetic data from a single oral dose of BPA 
administered to pregnant mice on gestational 
day 15 for calibrating their kinetic model. 
Simulations using their PBTK model indi-
cated that (total) BPA was rapidly transferred 
through the placenta to the fetus and that it was 
only slowly eliminated from the fetal compart-
ment. It should be stressed that this model was 
calibrated using data for total (unconjugated 
plus conjugated) BPA, so it did not specifically 
estimate the toxico  kinetics of unconjugated 
BPA. As far as we are aware, no other PBTK 
model for BPA in pregnant rodents or preg-
nant humans has been constructed. Additional 
and more refined PBTK models of unconju-
gated BPA in pregnant rodents and humans 
are therefore urgently needed.
Current PBTK models for BPA do not 
take into consideration the influence of local 
deconjugation of BPA metabolites at or in the 
vicinity of target tissues. Ginsberg and Rice 
(2009) recently discussed literature reports 
supporting the biological plausibility of local 
deglucuronidation of BPA glucuronide occur-
ring at a number of target tissues, such as 
placenta and the fetal compartment. For 
instance, Takahashi and Oishi (2000) dem-
onstrated that placenta has rather extensive 
β-glucuronidase activity and that liver and 
kidneys show much higher unconjugated 
BPA levels than blood. More information is 
needed to determine if, in fact, BPA is decon-
jugated in situ; if so, this should be added to 
future models.
Finally, a recent study determined that 
there is a linear relationship between applied 
doses and circulating unconjugated BPA con-
centrations (Vandenberg et al. 2007). This 
linear relationship was used to back-calculate 
the applied dose needed to generate the con-
centrations of unconjugated BPA that have 
been repeatedly meas  ured in environmentally 
exposed humans; the applied dose needed to 
achieve circulating BPA levels of 1–3 ng/mL 
blood that have been detected in biomonitor-
ing studies (Table 3) exceeded 500 µg/kg/day. 
This matches the predictions from the PBTK 
model developed by Shin et al. (2004), which 
clearly indicated that doses of 100 mg every 
24 hr for 10 days were needed to produce 
blood levels of 1.3 ng/mL in rats. These data 
need to be verified, but if true, they provide 
strong evidence that one cannot use urine   
levels to back-calculate to exposure levels.
Future Directions and 
Research Needs
Throughout this review we have mentioned 
research needs; these are summarized below.
We suggest that several small biomonitor-
ing studies performed previously should be 
repeated using large reference populations. 
First, it is imperative that estimates of uri-
nary BPA levels over 24 hr be undertaken. 
Second, there is a need for obtaining multiple 
samples of blood and urine from individuals 
to assess variability of exposure over time, 
likely encompassing weeks, months, or years. 
Finally, large-scale biomonitoring studies 
across the life span are needed to confirm lev-
els of total and unconjugated BPA in blood. 
These studies need to compare exposure levels 
in men and women, adults, neonates, children 
(spanning the pre  pubertal to pubertal period), 
pregnant and nonpregnant women, and obese 
and non  obese individuals, and across disease 
states. It is clear from animal studies that 
develop  mental periods (in utero and neo  natal 
periods) are the most sensitive to BPA; thus, 
special attention should be given to assess-
ment of total and unconjugated BPA in these 
vulnerable populations.
More studies are needed to examine preg-
nancy outcomes from large groups of racially 
and socio  economically diverse women, relat-
ing them to internal exposure levels through-
out pregnancy. It has been hypothesized 
that racial disparities in exposures to BPA 
and other endocrine-disrupting chemicals 
may account for the reduced fetal survival 
and birth weight of offspring (Ranjit et al. 
2010). Recent epidemiology studies suggest 
relationships between urinary BPA concentra-
tions and fertility end points (Meeker et al. 
2010; Mok-Lin et al. 2009). Additional stud-
ies are needed to extend these findings and 
also to define the levels of total and unconju-
gated BPA in ovarian follicular fluid, semen, 
amniotic fluid, and cord blood to relate to 
reproductive disease outcomes and adult con-
sequences.
Human toxicokinetic studies of BPA that 
employ sensitive methods across physiological 
states and age groups are needed. In addition, 
studies directly comparing the toxico  kinetics 
of BPA metabolism in humans and laboratory 
animals will help to determine if animals can 
accurately predict human metabolism.
Studies are needed to identify all sources 
of exposure and to assess the daily dose of BPA 
actually coming from the oral route versus 
other routes. Measurement of BPA in all food 
and drink sources and in indoor and outdoor 
air samples could be mandated by legislative 
actions.Vandenberg et al.
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Longitudinal studies in children linking 
developmental exposures to BPA and later-
onset diseases are especially important and 
needed. Two epidemiological studies have 
related adult urinary BPA concentrations to 
disease outcomes such as obesity, type 2 dia-
betes, and cardiovascular disease (Lang et al. 
2008; Melzer et al. 2010), all of which are on 
the rise. Studies that focus on relating BPA 
exposure to disease outcomes should also con-
trol for dietary phyto  estrogen exposure and 
consider mixture effects.
In addition to these specific data needs, 
it is important to take advantage of the 
NHANES data and database (http://www.
cdc.gov/nchs/nhanes.htm) for assessment of 
BPA levels and the relationship of those levels 
and disease outcomes. Several recent stud-
ies are excellent examples of using this data-
base to answer important questions relating to 
BPA exposure and linking BPA exposures to 
disease outcomes (Lang et al. 2008; Stahlhut 
et al. 2009). The NHANES database is a 
virtual treasure of data awaiting analysis and 
comparison.
Conclusions
We believe that human biomonitoring data 
clearly indicate that the general population is 
exposed to BPA ubiquitously, including signif-
icant internal exposures to unconjugated BPA. 
More important, animal studies suggest that 
fetuses and children are particularly vulnerable 
to BPA exposures and, at the same time, are 
exposed to higher levels of unconjugated BPA. 
The two toxicokinetic studies performed 
to date (Volkel et al. 2002, 2005), which sug-
gest that human exposure is negligible, have 
significant flaws and are therefore not reli-
able for risk assessment purposes. Further, the 
biomonitoring data, coupled with predictions 
from PBTK models, indicate that human 
exposures are higher than have been suggested 
from the toxico  kinetic studies. Weighing all 
the evidence available to date—because of the 
significant data showing human exposures to 
unconjugated BPA and animal data indicat-
ing increased susceptibility to disease at levels 
found in humans—we recommend that the 
precautionary principle be followed until fur-
ther data are available on exposure of fetuses 
and children to BPA. The health of the public 
is at stake.
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